Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
Therapeutic Advances in Medical Oncology|January 2, 2014
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implicationsRyan D Gentzler, Jyoti D PatelThoracic Surgery Clinics|April 25, 2020
Epidermal Growth Factor Receptor MutationsErin M McLoughlin, Ryan D GentzlerThe Oncologist|February 10, 2015
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerRyan D Gentzler, Melissa L JohnsonJournal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
Optimal first-line and maintenance treatments for advanced-stage nonsquamous non-small cell lung cancerRyan D Gentzler, Jyoti D PatelCurrent Oncology Reports|August 18, 2020
Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant ImmunotherapyRyan D Gentzler, David O Riley, Linda W MartinCurrent Treatment Options in Oncology|August 31, 2013
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of useRyan D Gentzler, Sarah E Yentz, Jyoti D PatelInternational Journal of Environmental Research and Public Health|November 13, 2021
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung CancerBethany Jablonski Horton, Nolan A Wages, Ryan D GentzlerExpert Opinion on Therapeutic Targets|April 13, 2012
An overview of the mTOR pathway as a target in cancer therapyRyan D Gentzler, Jessica K Altman, Leonidas C PlataniasLeukemia Research Reports|December 28, 2013
Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: A case of imatinib-responsivenessRyan D Gentzler, Alex C Minella, Brady L SteinTranslational Lung Cancer Research|December 3, 2015
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)Richard D Hall, Tri M Le, Daniel E Haggstrom, et al.Pageof 5